# MIRASOL / GOG-3045

Source: https://onco.cc/trials/mirasol/  
OnCo record `mirasol` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The first ADC to extend life in ovarian cancer, for the roughly one-third of tumours with high folate receptor alpha.

## Summary

MIRASOL, also GOG-3045, trial NCT04209855 sponsored by ImmunoGen, now AbbVie, and published in the New England Journal of Medicine in 2023, produced the first antibody-drug conjugate to extend life in ovarian cancer, for the roughly one-third of platinum-resistant tumours with high folate receptor alpha expression. It randomised 453 women with one to three prior lines to mirvetuximab soravtansine or chemotherapy, met its primary progression-free survival endpoint and improved overall survival, leading to full approval in March 2024; ocular toxicity is frequent but reversible with eye-drop prophylaxis. OnCo links it to ovarian cancer, antibody-drug conjugates, folate receptor alpha, mirvetuximab soravtansine, Kathleen N. Moore, Ursula A. Matulonis and the GOG Foundation. Whether the drug can move into platinum-sensitive or maintenance settings is the open question.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT04209855
- Phase: 3
- Setting: Platinum-resistant ovarian cancer with high folate receptor alpha expression, 1-3 prior lines: mirvetuximab soravtansine vs chemotherapy
- Sponsor: ImmunoGen (AbbVie)
- Enrolled: 453
- Result: OS 16.46 vs 12.75 months (HR 0.67).
- Outcomes: Progression-free survival: Mirvetuximab 5.62 months vs Chemotherapy 3.98 months, HR 0.65; Overall survival: Mirvetuximab 16.46 months vs Chemotherapy 12.75 months, HR 0.67

## Sources

- ClinicalTrials.gov NCT04209855: https://clinicaltrials.gov/study/NCT04209855
- NEJM 2023: https://www.nejm.org/doi/full/10.1056/NEJMoa2309169

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [Folate receptor alpha](https://onco.cc/targets/folr1/)
- drugs: [Mirvetuximab soravtansine](https://onco.cc/drugs/mirvetuximab-soravtansine/)
- companies: [GOG Foundation](https://onco.cc/companies/gog-foundation/)
- people: [Kathleen N. Moore](https://onco.cc/people/kathleen-moore/), [Ursula A. Matulonis](https://onco.cc/people/ursula-matulonis/)
- key papers: [MIRASOL: mirvetuximab soravtansine versus chemotherapy in folate receptor alpha-high platinum-resistant ovarian cancer](https://onco.cc/key-papers/paper-mirasol-nejm-2023/)

---
JSON: https://onco.cc/api/v1/entities/mirasol.json